Development and Chimpanzee Testing of a Vaccine against Human Hepatitis B
Summary Highly purified hepatitis B virus surface antigen (Australia antigen) purified by physical and chemical procedures from infected human plasma was used to prepare hepatitis B vaccine. The purified antigen was treated with formalin and the vaccine was tested exhaustively for safety by ordinary...
Gespeichert in:
| Veröffentlicht in: | Experimental biology and medicine (Maywood, N.J.) N.J.), 1976-04, Vol.151 (4), p.694-700 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 700 |
|---|---|
| container_issue | 4 |
| container_start_page | 694 |
| container_title | Experimental biology and medicine (Maywood, N.J.) |
| container_volume | 151 |
| creator | Buynak, Eugene B. Roehm, Robert R. Tytell, Alfred A. Bertland, Alexander U. Lampson, George P. Hilleman, Maurice R. |
| description | Summary
Highly purified hepatitis B virus surface antigen (Australia antigen) purified by physical and chemical procedures from infected human plasma was used to prepare hepatitis B vaccine. The purified antigen was treated with formalin and the vaccine was tested exhaustively for safety by ordinary procedures and additionally in marmosets (for live hepatitis A virus) and in chimpanzees (for live hepatitis B virus). The vaccine was highly potent, inducing antibody in guinea pigs, grivet monkeys, and chimpanzees given three doses of vaccine containing up to 20 μg of hepatitis B antigen per dose. A protective efficacy trial was carried out in chimpanzees that were given three doses of vaccine subcutaneously and then challenged intravenously with 1000 chimpanzee infectious doses of human hepatitis B virus. All of five unvaccinated control animals developed hepatitis B virus an-tigenemia following challenge and all of six vaccinated animals were protected, including one animal that had failed to develop detectable antibody following vaccination. |
| doi_str_mv | 10.3181/00379727-151-39288 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_83259790</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.3181_00379727-151-39288</sage_id><sourcerecordid>83259790</sourcerecordid><originalsourceid>FETCH-LOGICAL-c337t-266a4f812d5f48711f368f354b25d2b49f43db096609d67ab17ba1ce1a1d4f6f3</originalsourceid><addsrcrecordid>eNp9kLtOwzAUhi3ErRReADF4Ygv1Jb6NUC6tVImlsFpOYhdXiRPiBAmenpQURqYznO__dc4HwCVGNxRLPEOICiWISDDDCVVEygMwwYyyhHKlDsFkByQ74hScxbhFCDNB-Ak4llgQRSdgeW8_bFk3lQ0dNKGA8zdfNSZ8WQvXNnY-bGDtoIGvJs99sNBsjA-xg4u-MgEubGM63_kI787BkTNltBf7OQUvjw_r-SJZPT8t57erJKdUdAnh3KROYlIwl0qBsaNcOsrSjLCCZKlyKS0ypDhHquDCZFhkBucWG1ykjjs6Bddjb9PW7_1woq58zG1ZmmDrPmpJCVNCoQEkI5i3dYytdbppfWXaT42R3unTv_r0oE__6BtCV_v2Pqts8RcZfQ3r2biOZmP1tu7bMPz6X-E3DTZ3LA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>83259790</pqid></control><display><type>article</type><title>Development and Chimpanzee Testing of a Vaccine against Human Hepatitis B</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Buynak, Eugene B. ; Roehm, Robert R. ; Tytell, Alfred A. ; Bertland, Alexander U. ; Lampson, George P. ; Hilleman, Maurice R.</creator><creatorcontrib>Buynak, Eugene B. ; Roehm, Robert R. ; Tytell, Alfred A. ; Bertland, Alexander U. ; Lampson, George P. ; Hilleman, Maurice R.</creatorcontrib><description>Summary
Highly purified hepatitis B virus surface antigen (Australia antigen) purified by physical and chemical procedures from infected human plasma was used to prepare hepatitis B vaccine. The purified antigen was treated with formalin and the vaccine was tested exhaustively for safety by ordinary procedures and additionally in marmosets (for live hepatitis A virus) and in chimpanzees (for live hepatitis B virus). The vaccine was highly potent, inducing antibody in guinea pigs, grivet monkeys, and chimpanzees given three doses of vaccine containing up to 20 μg of hepatitis B antigen per dose. A protective efficacy trial was carried out in chimpanzees that were given three doses of vaccine subcutaneously and then challenged intravenously with 1000 chimpanzee infectious doses of human hepatitis B virus. All of five unvaccinated control animals developed hepatitis B virus an-tigenemia following challenge and all of six vaccinated animals were protected, including one animal that had failed to develop detectable antibody following vaccination.</description><identifier>ISSN: 0037-9727</identifier><identifier>ISSN: 1535-3702</identifier><identifier>EISSN: 1535-3699</identifier><identifier>DOI: 10.3181/00379727-151-39288</identifier><identifier>PMID: 817293</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Animals ; Antibodies, Viral - biosynthesis ; Guinea Pigs ; Haplorhini ; Hepatitis B - immunology ; Hepatitis B - prevention & control ; Hepatitis B Antibodies - biosynthesis ; Hepatitis B Antigens ; Hepatitis B virus - immunology ; Pan troglodytes ; Vaccines</subject><ispartof>Experimental biology and medicine (Maywood, N.J.), 1976-04, Vol.151 (4), p.694-700</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c337t-266a4f812d5f48711f368f354b25d2b49f43db096609d67ab17ba1ce1a1d4f6f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/817293$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Buynak, Eugene B.</creatorcontrib><creatorcontrib>Roehm, Robert R.</creatorcontrib><creatorcontrib>Tytell, Alfred A.</creatorcontrib><creatorcontrib>Bertland, Alexander U.</creatorcontrib><creatorcontrib>Lampson, George P.</creatorcontrib><creatorcontrib>Hilleman, Maurice R.</creatorcontrib><title>Development and Chimpanzee Testing of a Vaccine against Human Hepatitis B</title><title>Experimental biology and medicine (Maywood, N.J.)</title><addtitle>Proc Soc Exp Biol Med</addtitle><description>Summary
Highly purified hepatitis B virus surface antigen (Australia antigen) purified by physical and chemical procedures from infected human plasma was used to prepare hepatitis B vaccine. The purified antigen was treated with formalin and the vaccine was tested exhaustively for safety by ordinary procedures and additionally in marmosets (for live hepatitis A virus) and in chimpanzees (for live hepatitis B virus). The vaccine was highly potent, inducing antibody in guinea pigs, grivet monkeys, and chimpanzees given three doses of vaccine containing up to 20 μg of hepatitis B antigen per dose. A protective efficacy trial was carried out in chimpanzees that were given three doses of vaccine subcutaneously and then challenged intravenously with 1000 chimpanzee infectious doses of human hepatitis B virus. All of five unvaccinated control animals developed hepatitis B virus an-tigenemia following challenge and all of six vaccinated animals were protected, including one animal that had failed to develop detectable antibody following vaccination.</description><subject>Animals</subject><subject>Antibodies, Viral - biosynthesis</subject><subject>Guinea Pigs</subject><subject>Haplorhini</subject><subject>Hepatitis B - immunology</subject><subject>Hepatitis B - prevention & control</subject><subject>Hepatitis B Antibodies - biosynthesis</subject><subject>Hepatitis B Antigens</subject><subject>Hepatitis B virus - immunology</subject><subject>Pan troglodytes</subject><subject>Vaccines</subject><issn>0037-9727</issn><issn>1535-3702</issn><issn>1535-3699</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1976</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kLtOwzAUhi3ErRReADF4Ygv1Jb6NUC6tVImlsFpOYhdXiRPiBAmenpQURqYznO__dc4HwCVGNxRLPEOICiWISDDDCVVEygMwwYyyhHKlDsFkByQ74hScxbhFCDNB-Ak4llgQRSdgeW8_bFk3lQ0dNKGA8zdfNSZ8WQvXNnY-bGDtoIGvJs99sNBsjA-xg4u-MgEubGM63_kI787BkTNltBf7OQUvjw_r-SJZPT8t57erJKdUdAnh3KROYlIwl0qBsaNcOsrSjLCCZKlyKS0ypDhHquDCZFhkBucWG1ykjjs6Bddjb9PW7_1woq58zG1ZmmDrPmpJCVNCoQEkI5i3dYytdbppfWXaT42R3unTv_r0oE__6BtCV_v2Pqts8RcZfQ3r2biOZmP1tu7bMPz6X-E3DTZ3LA</recordid><startdate>197604</startdate><enddate>197604</enddate><creator>Buynak, Eugene B.</creator><creator>Roehm, Robert R.</creator><creator>Tytell, Alfred A.</creator><creator>Bertland, Alexander U.</creator><creator>Lampson, George P.</creator><creator>Hilleman, Maurice R.</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>197604</creationdate><title>Development and Chimpanzee Testing of a Vaccine against Human Hepatitis B</title><author>Buynak, Eugene B. ; Roehm, Robert R. ; Tytell, Alfred A. ; Bertland, Alexander U. ; Lampson, George P. ; Hilleman, Maurice R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c337t-266a4f812d5f48711f368f354b25d2b49f43db096609d67ab17ba1ce1a1d4f6f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1976</creationdate><topic>Animals</topic><topic>Antibodies, Viral - biosynthesis</topic><topic>Guinea Pigs</topic><topic>Haplorhini</topic><topic>Hepatitis B - immunology</topic><topic>Hepatitis B - prevention & control</topic><topic>Hepatitis B Antibodies - biosynthesis</topic><topic>Hepatitis B Antigens</topic><topic>Hepatitis B virus - immunology</topic><topic>Pan troglodytes</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Buynak, Eugene B.</creatorcontrib><creatorcontrib>Roehm, Robert R.</creatorcontrib><creatorcontrib>Tytell, Alfred A.</creatorcontrib><creatorcontrib>Bertland, Alexander U.</creatorcontrib><creatorcontrib>Lampson, George P.</creatorcontrib><creatorcontrib>Hilleman, Maurice R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Experimental biology and medicine (Maywood, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Buynak, Eugene B.</au><au>Roehm, Robert R.</au><au>Tytell, Alfred A.</au><au>Bertland, Alexander U.</au><au>Lampson, George P.</au><au>Hilleman, Maurice R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development and Chimpanzee Testing of a Vaccine against Human Hepatitis B</atitle><jtitle>Experimental biology and medicine (Maywood, N.J.)</jtitle><addtitle>Proc Soc Exp Biol Med</addtitle><date>1976-04</date><risdate>1976</risdate><volume>151</volume><issue>4</issue><spage>694</spage><epage>700</epage><pages>694-700</pages><issn>0037-9727</issn><issn>1535-3702</issn><eissn>1535-3699</eissn><abstract>Summary
Highly purified hepatitis B virus surface antigen (Australia antigen) purified by physical and chemical procedures from infected human plasma was used to prepare hepatitis B vaccine. The purified antigen was treated with formalin and the vaccine was tested exhaustively for safety by ordinary procedures and additionally in marmosets (for live hepatitis A virus) and in chimpanzees (for live hepatitis B virus). The vaccine was highly potent, inducing antibody in guinea pigs, grivet monkeys, and chimpanzees given three doses of vaccine containing up to 20 μg of hepatitis B antigen per dose. A protective efficacy trial was carried out in chimpanzees that were given three doses of vaccine subcutaneously and then challenged intravenously with 1000 chimpanzee infectious doses of human hepatitis B virus. All of five unvaccinated control animals developed hepatitis B virus an-tigenemia following challenge and all of six vaccinated animals were protected, including one animal that had failed to develop detectable antibody following vaccination.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>817293</pmid><doi>10.3181/00379727-151-39288</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0037-9727 |
| ispartof | Experimental biology and medicine (Maywood, N.J.), 1976-04, Vol.151 (4), p.694-700 |
| issn | 0037-9727 1535-3702 1535-3699 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_83259790 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Animals Antibodies, Viral - biosynthesis Guinea Pigs Haplorhini Hepatitis B - immunology Hepatitis B - prevention & control Hepatitis B Antibodies - biosynthesis Hepatitis B Antigens Hepatitis B virus - immunology Pan troglodytes Vaccines |
| title | Development and Chimpanzee Testing of a Vaccine against Human Hepatitis B |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T09%3A13%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20and%20Chimpanzee%20Testing%20of%20a%20Vaccine%20against%20Human%20Hepatitis%20B&rft.jtitle=Experimental%20biology%20and%20medicine%20(Maywood,%20N.J.)&rft.au=Buynak,%20Eugene%20B.&rft.date=1976-04&rft.volume=151&rft.issue=4&rft.spage=694&rft.epage=700&rft.pages=694-700&rft.issn=0037-9727&rft.eissn=1535-3699&rft_id=info:doi/10.3181/00379727-151-39288&rft_dat=%3Cproquest_cross%3E83259790%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=83259790&rft_id=info:pmid/817293&rft_sage_id=10.3181_00379727-151-39288&rfr_iscdi=true |